Bluejay Diagnostics, Inc.

Equities

BJDX

US0956334009

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2024 am IST			5-day change	1st Jan Change
1.63 ^USD	-40.73%		-44.45%	-83.30%

26/06	Buejay Diagnostics, Inc Announces Results from the Primary Analysis of SYMON-I	CI
31/05	Bluejay Diagnostics, Inc. announced a financing transaction	CI

Bluejay Diagnostics, Inc. Appoints Mark Feinberg as Chief Medical Advisor

January 05, 2022 at 06:45 pm IST

Bluejay Diagnostics, Inc. (‘Bluejay') announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay's clinical development programs and provide strategic medical and scientific leadership to the Company. Dr. Mark W. Feinberg is a cardiovascular medicine specialist at Brigham and Women's Hospital (BWH) and an associate professor of medicine at Harvard Medical School (HMS).

He is also an affiliated faculty member at the Harvard Stem Cell Institute.

Latest news about Bluejay Diagnostics, Inc.

Buejay Diagnostics, Inc Announces Results from the Primary Analysis of SYMON-I	26/06	CI
Bluejay Diagnostics, Inc. announced a financing transaction	31/05	CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Bluejay Diagnostics, Inc. Appoints Neil Dey as Principal Financial and Accounting Officer	03/04	CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Top Premarket Decliners	28/12	MT
Top Midday Decliners	28/12	MT
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients	27/12	CI
Bluejay Diagnostics Starts Clinical Study of Symphony IL-6 Test in Sepsis Patients; Shares Fall	27/12	MT
Bluejay Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Bluejay Diagnostics, Inc. Announces CFO Changes	03/23/03	CI
Bluejay Diagnostics, Inc. announced that it has received $1.59084 million in funding	28/23/28	CI
Sector Update: Health Care Stocks Climbing Late Afternoon	26/23/26	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	25/23/25	MT
Bluejay Diagnostics to Raise $1.6 Million in Registered Direct Offering	25/23/25	MT
Bluejay Diagnostics, Inc. announced that it expects to receive $1.59084 million in funding	24/23/24	CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
North American Morning Briefing : Stocks Seen -2-	04/23/04	DJ
Dawson James Downgrades Bluejay Diagnostics to Neutral From Buy	03/23/03	MT
Bluejay Diagnostics Files $25 Million Mixed Shelf	06/23/06	MT
Bluejay Diagnostics, Inc. Updates Symphony IL-6 Regulatory Strategy	19/23/19	CI
Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
Sector Update: Health Care Stocks Lifted with Broader Markets	22/23/22	MT
Top Midday Decliners	21/23/21	MT
Sector Update: Health Care Stocks Still Struggling for Firm Direction Tuesday Afternoon	21/23/21	MT

Chart Bluejay Diagnostics, Inc.

Duration

Period

More charts

Company Profile

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.

Sector

Biotechnology & Medical Research

Calendar

07/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
BLUEJAY DIAGNOSTICS, INC.	-83.30%	6L
EXACT SCIENCES CORPORATION	-40.31%	814.88Cr
GUARDANT HEALTH, INC.	+8.65%	359.64Cr
IOVANCE BIOTHERAPEUTICS, INC.	-0.25%	226.94Cr
BGI GENOMICS CO., LTD.	-24.56%	190.05Cr
VERACYTE, INC.	-18.21%	172.01Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	+5.95%	92Cr
CAREDX, INC	+16.75%	73Cr
SEEGENE, INC.	-10.48%	68Cr
CURIOX BIOSYSTEMS CO., LTD	-0.60%	29Cr

Bio Diagnostics & Testing